COMPANY PROFILE

Encentuate

Explore full profile

Identity and access management solutions without requiring enterprises to change their existing it infrastructure

Foster City, United StatesFounded 2001Biotech & Life Sciences

Valuation $50–100M Last recorded · 2005

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Encentuate

Encentuate specializes in providing cloud-native solutions designed to help businesses modernize their application portfolios, enhance security measures, and accelerate digital transformation initiatives. Operating primarily within the enterprise sector, Encentuate serves a diverse range of clients from various industries who are looking to leverage cloud technology for business growth and operational efficiency. The company offers a flexible licensing model that can be tailored to meet specific business needs, ensuring that clients can run their applications on public clouds, on-premises, or private clouds as required. Encentuate's business model revolves around offering subscription-based services and consulting, generating revenue through long-term client engagements and value-added services. By focusing on a comprehensive approach that blends business strategy, design, and technology, Encentuate enables enterprises to break through traditional barriers and adopt agile methodologies for scalable growth.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2001
Headquarters: Foster City, United States
Employees: 11
Open positions: None listed
Dealroom signal: 23.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITION✓Exit	Mar 2008	$0	—	IBM	—
SERIES B✓Equity / VC	Mar 2005	$16M	$64M	VSP Capital · Gabriel Venture Partners · August Capital	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Encentuate website traffic

Latest recorded traffic for Encentuate is 0 monthly website visits. Encentuate's team grew 0% over the past year.

Latest monthly visits0 1-year team growth0%

Monthly website visitsFeb 2020–May 2020

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
GTGemini TherapeuticsInnovative therapies targeting genetically defined subpopulations in dry AMD and related diseases	Cambridge, United States	Operational	1	$45M	$217M
STStorm TherapeuticsSmall molecule therapies targeting RNA modifying enzymes	Cambridge, United Kingdom	Operational
MOMorphogen-IXEngineered protein therapeutics for pulmonary arterial hypertension	Babraham, United Kingdom	Acquired
STSpur TherapeuticsGene therapies for Gaucher, Parkinson's, and cardiovascular diseases	Stevenage, United Kingdom	Acquired
ATAt-biotechHealth care company that creates technological automation and safety solutions for the healthcare sector	Madrid, Spain	Operational
MLMedGenome LabsA genomics-driven research and diagnostics company with a mission to improve global health by decoding the genetic information contained in an individual’s genome	Foster City, United States	Operational
TBTELA BioLife science company offering surgical reconstruction	Malvern, United States	Operational
BTBlue Belt TechnologiesA medical device company that focuses on technology and capabilities of surgical instrumentation	Pittsburgh, United States	Acquired